SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Status:
Recruiting
Trial end date:
2031-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor,
mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).